Metabolic peptides are at the forefront of modern research into weight management, insulin sensitivity, and energy metabolism. Semaglutide is being studied for its potential role in metabolic regulation and related pathways.
A GLP-1 receptor agonist approved for type 2 diabetes and obesity (Ozempic/Wegovy). Demonstrates significant cardiovascular risk reduction and is under study for NASH and neurodegeneration.
Also Known As
Ozempic, Wegovy, Rybelsus
What is Semaglutide?
Semaglutide is classified under the Metabolic category of peptides. A GLP-1 receptor agonist approved for type 2 diabetes and obesity (Ozempic/Wegovy). Demonstrates significant cardiovascular risk reduction and is under study for NASH and neurodegeneration.
Mechanism of Action: A GLP-1 receptor agonist with 94% homology to native GLP-1, featuring an amino acid substitution and fatty acid chain that enable binding to albumin, extending its half-life to approximately 7 days. It enhances insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic appetite centers.
Metabolic Research & Applications
Primary Research Areas: Type 2 diabetes management, obesity treatment, cardiovascular risk reduction, NASH/NAFLD, addiction research.
Key Research Findings: The STEP trials demonstrated average weight loss of 15-17% with semaglutide 2.4mg weekly. The SELECT trial showed a 20% reduction in major cardiovascular events. Emerging research explores benefits in kidney disease, Alzheimer's, and substance use disorders.
Safety Profile & Considerations
Common side effects include nausea, vomiting, diarrhea, and constipation. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumors (observed in rodents). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
Related Research Topics
Understanding Semaglutide requires familiarity with these related concepts in metabolic research. Each topic represents a broader field that intersects with current peptide research.
References & Further Reading
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
Stay Updated on Peptide Research
Get the latest science-backed articles on peptides delivered to your inbox.